Costimulation as a platform for the development of vaccines: A peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4319-4326

  Sharma, Rajesh K ^a   Elpek, Kutlu G ^a   Yolcu, Esma S ^a   Schabowsky, Rich Henry ^a   Zhao, Hong ^a   Bandura Morgan, Laura ^a   Shirwan, Haval ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CANCER VACCINE; CD137 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; LIPOPOLYSACCHARIDE; PROTEIN E7; SURVIVIN; THROMBOPOIETIN RECEPTOR; TOLL LIKE RECEPTOR AGONIST; TRANSCRIPTION FACTOR FOXP3;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLONAL ANERGY; CONTROLLED STUDY; CPG ISLAND; DENDRITIC CELL; EFFECTOR CELL; ERADICATION THERAPY; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOMODULATION; INNATE IMMUNITY; LUNG CARCINOMA; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; THERAPY EFFECT; UTERINE CERVIX CANCER; VACCINE PRODUCTION;

4-1BB LIGAND; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; LUNG NEOPLASMS; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROTUBULE-ASSOCIATED PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 66249141668     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3141     Document Type: Article

References (40)

1. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003;3:630-41.
2. Ishii KJ, Akira S. Toll or toll-free adjuvant path toward the optimal vaccine development. J Clin Immunol 2007;27:363-71.
3. Watts TH. TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 2005;23:23-68.
4. Uno T, Takeda K, Kojima Y, et al. Eradication of established tumors in mice by a combination antibodybased therapy. Nat Med 2006;12:693-8.
5. Myers L, Lee SW, Rossi RJ, et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol 2006;18:325-33.
6. Piconese S, Valzasina B, Colombo MP. OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection. J Exp Med 2008;205:825-39.
7. + CTL to cause tumor eradication. J Immunol 2004;173:6753-9.
8. Hixon JA, Blazar BR, Anver MR, Wiltrout RH, Murphy WJ. Antibodies to CD40 induce a lethal cytokine cascade after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 2001;7:136-43.
9. Niu L, Strahotin S, Hewes B, et al. Cytokine-mediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007;178:4194-213.
10. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006;355:1018-28.
11. Wilcox RA, Chapoval AI, Gorski KS, et al. Cutting edge: expression of functional CD137 receptor by dendritic cells. J Immunol 2002;168:4262-7.
12. Saoulli K, Lee SY, Cannons JL, et al. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998;187:1849-62.
13. + T cells confers resistance to suppression by virus-induced regulatory T cells. J Immunol 2008;180:5267-74.
14. + regulatory T cells. J Immunol 2004;173:2428-34.
15. Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P, Lang F. Production of recombinant human trimeric CD137L(4-1BB L). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem 2005;280:41472-81.
16. + T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007;179:7295-304.
17. Grakoui A, Bromley SK, Sumen C, et al. The immunological synapse: a molecular machine controlling T cell activation. Science 1999;285:221-7.
18. Kilinc MO, Mukundan L, Yolcu ES, Singh NP, Suttles J, Shirwan H. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp Mol Pathol 2006;80:252-61.
19. Yolcu ES, Askenasy N, Singh NP, Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002;17:795-808.
20. + Treg cells. Transplantation 2005;79:1492-7.
21. Berraondo P, Nouze C, Preville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007;67:8847-55.
22. Bukczynski J, Wen T, Ellefsen K, Gauldie J, Watts TH. Costimulatory ligand 4-1BBL(C D137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses. Proc Natl Acad Sci U S A 2004;101:1291-6.
23. Cannons JL, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001;167:1313-24.
24. Radhakrishnan S, Celis E, Pease LR. B7-DC crosslinking restores antigen uptake and augments antigen-presenting cell function by matured dendritic cells. Proc Natl Acad Sci U S A 2005;102:11438-43.
25. + T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol 2007;178:6840-8.
26. Myers LM, Vella AT. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. Trends Immunol 2005;26:440-6.
27. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995;1:1297-302.
28. Posner MC, Niedzwiecki D, Venook AP, et al. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: Cancer and Leukemia Group B study 89903. Ann Surg Oncol 2008;15:158-64.
29. Huang Y, Obholzer N, Fayad R, Qiao L. Turning on/off tumor-specific CTL response during progressive tumor growth. J Immunol 2005;175:3110-6.
30. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-90.
31. + T cells. J Leukoc Biol 2005;78:1273-80.
32. Weeratna RD, Makinen SR, McCluskie MJ, Davis HL. TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 2005;23:5263-70.
33. Bertram EM, Lau P, Watts TH. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002;168:3777-85.
34. Waller EC, McKinney N, Hicks R, Carmichael AJ, Sissons JG, Wills MR. Differential costimulation through CD137 (4-1BB) restores proliferation of human virus-specific "effector memory" (CD28(-) CD45RA(HI)) CD8(+) T cells. Blood 2007;110:4360-6.
35. + T cell responses. Nat Immunol 2002;3:536-41.
36. Wilcox RA, Flies DB, Zhu G, et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002;109:651-9.
37. Tuve S, Chen BM, Liu Y, et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res 2007;67:5929-39.
38. + T cell response. J Immunol 2007;178:5429-33.
39. + regulatory T cells. J Immunol 2004;173:4433-42.
40. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN type 1 signaling. J Immunol 2005;175:5601-5.